Sign in

CIK 0001806952 · Non-accelerated filer<br>Smaller reporting company

Lyell Immunopharma, Inc.

Sign in to watch
Ticker
LYEL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
833006753
Phone
650 695-0677
Business address
201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$18,766
in 4 filings

Net −$18,766. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Seely Lynn −$9K President and CEO sold <1% of stake
  2. Bulis Veronica Sanchez −$7K VP, Corporate Controller sold 3% of stake
  3. Lee Gary K. −$2K Chief Scientific Officer sold <1% of stake
  4. Hill Stephen J. −$1K Chief Operating Officer sold <1% of stake

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-11-10 Bulis Veronica Sanchez VP, Corporate Controller Sale −416 $15.93 $7K 14,383
2026-11-10 Lee Gary K. Chief Scientific Officer Sale −129 $15.93 $2K 16,091
2026-11-10 Hill Stephen J. Chief Operating Officer Sale −88 $15.93 $1K 16,728
2026-11-10 Seely Lynn President and CEO Sale −545 $15.93 $9K 63,354
2021-06-21 GLAXOSMITHKLINE PLC 10% owner Conversion +30,253,189 30,253,189
2021-06-21 GLAXOSMITHKLINE PLC 10% owner Conversion · Series AA Preferred Stock −30,253,189 0

Page 1 of 1 · 6 trades